The findings of the team provided the basis for considering ectopic tBid as a potential weapon in the fight against HCC, either alone or in conjunction with chemotherapeutic agents (such as doxorubicin, TNF-α, 5-fluorouracil) and/or radiotherapeutic interventions [199]. The gene discussed is BID; the disease is hepatocellular carcinoma.